Objective: In recent years, there has been a blossoming of studies examining cerebrospinal fluid (CSF) as a method of studying the pathophysiology of delirium. We systematically reviewed the literature for CSF studies in delirium and provide here a summary of the implications for our understanding of delirium pathophysiology. We also summarise the methods used for CSF analysis and discuss challenges and implications for future studies. Methods: In this systematic review, we screened MEDLINE, EMBASE, PsycINFO, Web of Science, PubMed and the Cochrane Library for articles on CSF biomarkers in delirium, published on 3 September 2016. Studies were required to use Diagnostic and Statistical Manual of Mental Disorders or International Classification of Diseases criteria for delirium or a validated tool. We excluded case reports. There were no other restrictions on study type. Results: We identified 3280 articles from our initial search, and 22 articles were included in this review. All studies were prospective, including over 400 patients with delirium and 700 controls. More than 70 different biomarkers were studied. Studies could not be compared with each other for meta-analysis because of their heterogeneity and varied widely in their risk of bias and quality assessments. Conclusions: The 22 studies identified in this review reveal a small but growing literature, in which many of the important hypotheses in delirium pathogenesis have been examined, but from which few firm conclusions can currently be drawn. Nevertheless, the overall interpretation of the literature supports the vulnerable brain concept, that is, that biomarker evidence of, for example, Alzheimer's disease pathology and/or neuroinflammation, is associated with delirium.
Introduction
Delirium is a common, serious and dramatic complication of acute medical illness associated with increased mortality and morbidity (Witlox et al., 2010; Inouye et al., 2013) . Recent evidence suggests that delirium predicts dementia in previously cognitively intact patients and is linked with accelerated decline in those with existing dementia (Davis et al., 2012; Krogseth et al., 2016; Davis et al., 2017) . Thus, delirium is a major public health concern, and research on pathophysiological mechanisms is urgently needed.
In recent years, there has been a blossoming of studies examining cerebrospinal fluid (CSF) for insights into the pathophysiology of delirium. CSF, a clear fluid surrounding the brain and providing mechanical support, also carries nutrients and signalling molecules to neurons and helps the clearance of metabolites into the blood (Johanson et al., 2008; Louveau et al., 2015) . The main advantage of utilising CSF to measure markers of the central nervous system (CNS) changes is that it communicates freely with the brain interstitial fluid that bathes the neurons. Some biochemical changes in the brain are thus reflected in the CSF, which may be regarded as an accessible, albeit imperfect, sample of the brain interstitial fluid (Blennow et al., 2010) . This provides an advantage over blood, as confirmed in studies of neurodegenerative disorders (Blennow et al., 2010) . Further, CSF has low protease activity, and most molecules do not change upon sampling if the sample is uncontaminated by blood (Johanson et al., 2008) . The main disadvantage is that lumbar puncture (LP) is an invasive procedure, and there are obvious ethical and practical difficulties in obtaining CSF specimens for research purposes from patients with delirium. Several recent CSF delirium studies have overcome this problem by exploiting the valuable opportunity afforded by spinal anaesthetic administration for surgical procedures, especially hip fracture surgery.
In 2011, Hall et al. published a systematic literature review of the eight existing studies of CSF in delirium . The 2011 review highlighted a paucity of research in this area; no clear conclusions emerged regarding delirium pathophysiology, with more detailed studies needed. This review serves as an update. We aimed to identify the current published literature examining CSF in delirium, and ask, do CSF biomarker concentrations relate to delirium incidence, severity, duration or subtype. We summarise what the current literature reveals about delirium pathophysiology and also the methods used for CSF analysis, and discuss challenges and implications for future studies.
Methods

Search strategy and selection criteria
We are reporting this systematic review according to the PRISMA guidelines (Liberati et al., 2009) . We searched MEDLINE, EMBASE, PsycINFO, Web of Science, PubMed and the Cochrane Library for studies published in English or Norwegian on 3 September 2016. Additionally, we hand-searched the bibliographies of relevant articles, performed a forward citation search in Web of Science for all studies examined and contacted experts in the field via the European Delirium Association. We used terms including Delirium or Acute Confusional State, and Cerebrospinal Fluid or Lumbar Puncture (see Appendix 1 for full search strategy and Appendix 2 for the study protocol).
Inclusion criteria were (i) that delirium was diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM III; DSM IIIR; DSM IV, DSM 5) or International Classification of Diseases (ICD) criteria or a method based upon this and (ii) that we could extract data on biomarker findings in CSF in delirium. Exclusion criteria were (i) case reports (no other restrictions on study type) and (ii) studies involving delirium tremens or hepatic encephalopathy or where neuropsychiatric systematic lupus erythematosus was the primary cause of delirium.
Data extraction and assessment of study quality and risk of bias R. J. H. and L. O. W. independently performed the search and identified articles for full text review. Included studies were agreed by consensus, and data were extracted by R. J. H., L. O. W. and E. C. We recorded the following: (a) study design and provenance; (b) number and characteristics of patients and controls and comparability of patient and control groups; (c) method used to diagnose delirium; (d) delirium severity, motor subtype and duration; (e) aetiology of delirium; (f) presence and method of assessment for underlying dementia; (g) method of obtaining CSF; (g) biomarkers studied; (i) preanalytical and analytical laboratory methodology; (j) main study findings; (k) statistical significance; and (l) statistical methods. Risk of bias was assessed according to the RoBANS tool (Kim et al., 2013) , with pre-determined criteria for low or high risk for each domain. We considered the principal confounding factor to be dementia. Risk of bias was assessed by R. J. H., L. O. W. and E. C. independently, and agreed by consensus.
Results
We identified 3280 articles from our initial search, and 2352 remained after removal of duplicates (Figure 1) . A total of 194 full-text articles were assessed for eligibility (Appendix 3), and 22 articles were included in the systematic review. The included articles reported data from nine research groups, including several collaborations (Table 1 ). All studies collected data on delirium status prospectively, although most collected CSF only once (with the exception of Koponen and Riekkinen (1990) and Hirsch et al. (2016) ). Over 400 patients with delirium and 700 controls were studied, although many are included in more than one article. There is some overlap of biomarkers studied by different research groups, and the differing results are discussed. Studies could not be compared with each other for meta-analysis due to study heterogeneity. Baseline characteristics of the included studies are presented in Table 1 , the main findings in Table 2 , and the results of the risk of bias assessment plus additional quality comments in Table 3 . Several studies examined biomarker relationships with delirium severity, few assessed motor subtype and none reported delirium duration. Overall, risk of bias varied, with smaller exploratory studies generally having higher risk and more recent larger studies having lower risk. Many 5-HIAA, 5-Hydroxyindole-acetic acid; Aβ40, Amyloid-β 1-40; Aβ42, Amyloid-β 1-42; AchE, Acetyl-cholinesterase; BLI, Beta Endorphin-like immunoreactivity; CNS, central nervous system; ELISA, enzyme-linked immunosorbent assay; GFAP, Glial Fibrillary Acidic Protein; HPLC, High-performance liquid chromatography; HVA, Homovanillic acid; IL, interleukin; IFN-γ -Interferon gamma; IGF, insulin like growt factor; NSE, Neuron-specific enolase; POCD, Post operative cognitive dysfunction; P-tau, phosphorylated tau; RIA, Radioimmunoassay;
sIL6R, soluble IL-6 receptor; S100B, S100 calcium-binding protein B; SLI, Somatostatin-like immunoreactivity; TNF, tumor necrosis factor; T-tau, total tau. ↑ 5HIAA in delirium in subgroup without dementia Amino acid levels tended to be highest in incident delirium IL, interleukin; IFN-γ, Interferon gamma; IGF, insulin like growth factor; MCP, monocyte chemotactic protein; MDAS, Memorial Delirium Assessment Scale; MMSE, Mini-Mental State Examination; NSE, Neuron-specific enolase; P-tau, phosphorylated tau; S100B, S100 calcium-binding protein B; sIL-6R, soluble IL-6 receptor; SLI, Somatostatin-like immunoreactivity;
TNF, tumor necrosis factor; T-tau, total tau. 
Risk markers of delirium
Dementia neuropathology markers
Dementia neuropathology markers were measured in three studies of patients undergoing orthopaedic surgery. Witlox et al. (2011) examined β-amyloid1-42 (Aβ42), total tau (t-tau) and phosphorylated tau (ptau) in hip fracture patients. There were no statistically significant differences in levels of these markers between those with or without post-operative delirium (preoperative delirium was excluded). Idland et al. (2017) also studied hip fracture patients. They found that, in patients without dementia, delirium was associated with lower CSF Aβ42 levels and higher t-tau levels and lower ratios of Aβ42 to t-tau and p-tau. In patients with dementia, CSF biomarker levels did not differ between those with and without delirium. The authors suggest that a possible explanation for the discrepancy with Witlox et al. (2011) is that the biomarker levels in the Dutch cohort were much closer to normal levels, indicating less AD pathology. Xie et al. (2014) studied elective arthroplasty patients. They found no significant difference in CSF Aβ42/tau ratio or Aβ40/tau ratio between groups with and without delirium. When they examined quartiles of the Aβ/tau ratios, they found a higher incidence of delirium in those in the lowest quartile for both ratios.
Disease markers of delirium
Neurotransmitters and hormones
Levels of neurotransmitter precursors, metabolites and metabolising enzymes and potentially neuroactive hormones have been measured in several studies, although few have been analysed in more than one study.
Somatostatin-like immunoreactivity and beta-endorphin-like immunoreactivity
The first CSF study was published in 1990 (Koponen and Riekkinen, 1990 ). An aetiologically heterogeneous group of older patients with delirium underwent a morning fasting LP on the day following their index admission, at 2 weeks after admission and at 1 and 4 years. Their control group was from a Healthy Ageing study. For the whole delirium group, they found a reduction in mean somatostatin-like immunoreactivity (SLI) level at index, 2 weeks and 1 and 4 years (Koponen et al., 1994b) and a reduction in mean beta-endorphin-like immunoreactivity (BLI) at index, 2 weeks and 1 year (Koponen and Riekkinen, 1990) .
Monoamine precursors and metabolites Koponen et al. (1994c) found that the principal serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) was higher in the subgroups with delirium superimposed on vascular dementia or no CNS disease. The levels stayed high at 2 weeks and 1 year in both groups. Watne et al. (2016) published analyses of 5-HIAA and aromatic amino acids, which are precursors for monoamines. They found that both phenylalanine and tyrosine (dopamine and noradrenaline precursors) and tryptophan (serotonin precursor) were higher in patients with delirium. In patients without dementia, 5-HIAA was also highest in delirium, paralleling the increase in tryptophan. Patients with dementia had lower levels of most amino acids compared with patients without dementia. Analyses stratified by dementia status, however, revealed that delirium was associated with higher levels of the same amino acids in both strata. Notably, the correlation between serum and CSF amino acids levels was poor.
Ramirez-Bermudez et al. (2008) examined homovanillic acid (HVA, a dopamine metabolite) in a cohort of patients with acute neurological symptoms requiring LP for a clinical indication. This cohort was younger and had a high proportion of CNS infections (43/51 patients) and HIV infection (16/51 patients). Although HVA was not significantly different between those with and without delirium, it was higher in patients with psychotic features such as hallucinations and delusions.
Acetylcholine Koponen et al. (1994a) found no association between delirium and acetylcholinesterase (AChE), the principle enzyme responsible for metabolising acetylcholine in the delirious group as a whole. However, there was a fall in levels of AChE between the 2-week and 1-year time points in the delirium subgroups with AD, multi-infarct dementia and hyperkinetic delirium, and a small but non-significant reduction in levels of AChE in the group with no CNS disease. Watne et al. (2014) analysed anticholinergic activity (AA) in patients with acute hip fracture from Oslo and Edinburgh and found that AA was not significantly different in delirium.
Cortisol Pearson et al. (2010) found cortisol levels to be higher in those with delirium than those without, in a small cohort of patients with acute hip fracture.
Inflammation
Neuroinflammation has been assessed in several studies. All studies included orthopaedic patients (hip fracture in all except for elective surgery in Hirsch et al., 2016) .
Cytokines and chemokines
MacLullich et al. (2011) measured six cytokines, but only interleukin (IL)-8 (33/36 samples) and IL-6 (3/36 samples) were above the detection limit. IL-8 was higher in patients with delirium at any stage. Westhoff et al. (2013) measured 41 different cytokines and chemokines, but only 16 were detectable in more than 50% of the samples. Fms-like tyrosine kinase-3 (Flt-3L), IL-1ra and IL-6 were significantly lower in patients with post-operative delirium (preoperative delirium was excluded). They detected, but found no difference in levels of, IL-8. The authors suggest that the findings could be interpreted that delirium is the result of a dysfunctional inflammatory state, where reduced anti-inflammatory mediators play a more important role than an increased proinflammatory activity. Cape et al. (2014) measured several inflammatory markers and a marker of astroglial activation (glial fibrillary acidic protein) in patients recruited in Edinburgh and Amsterdam. The investigators found that IL-1β was elevated in those with incident delirium, and IL-1ra was elevated in prevalent delirium. The CSF : serum ratio of IL-1β was higher in the delirium group. Glial fibrillary acidic protein was not significantly different between groups. Interferon-γ and insulin-like growth factor-1 were not detected in CSF, and IL-1β was detected in low concentrations. This study supports a role for the IL-1 family in delirium. The higher CSF : serum ratio of IL-1β, with no correlation between the two, suggests a CNS source of IL-1β. Neerland et al. (2016) examined C-reactive protein (CRP), IL-6 and soluble IL-6 receptor. In patients without prefracture cognitive impairment, CSF CRP was higher in delirium. There were no significant differences in delirium in IL-6 or soluble IL-6 receptor. The authors suggest that different pathophysiological mechanisms are important in different subgroups of patients. In particular, neuroinflammation may be more important in cohorts other than those with hip fracture.
A recent study reported longitudinal changes in CSF and plasma in 10 patients undergoing elective knee surgery (Hirsch et al., 2016 ). An indwelling spinal catheter was placed at the time of spinal anaesthesia and removed after 24 h. Plasma and CSF were collected preoperatively and at 3, 6 and 18 h post-operatively. Only one patient developed delirium, and CSF levels of the pro-inflammatory cytokines IL-6, IL-8 and monocyte chemotactic protein-1 showed a persistent increase in this patient. Intriguingly, levels of several pro-and antiinflammatory cytokines changed significantly postoperatively compared with baseline, and these changes were often more pronounced in CSF than plasma.
Neopterin
Neopterin, a biomarker of cell-mediated immunity and oxidative stress, has been measured in one study . Those who developed delirium after hip fracture had higher levels compared with those who did not become delirious. Neopterin levels were highest in patients with delirium superimposed on dementia and lowest in patients free from both conditions. The authors conclude that these findings support the neuroinflammation hypothesis in delirium and that delirium and dementia may have an additive effect.
Blood-cerebrospinal fluid barrier Hov et al. (2016) assessed the blood-CSF barrier integrity in hip fracture patients with Q-albumin (the ratio of CSF albumin to serum albumin). The majority of patients (88%) had intact blood-CSF barrier integrity, but all patients with barrier dysfunction (n = 14) had delirium (n = 11) or subsyndromal delirium (n = 3). The authors conclude that blood-CSF barrier dysfunction might be important for delirium, but it is not a prerequisite for delirium to develop.
Proteomics Poljak et al. (2014) recruited patients in two centres, Sydney (medical patients) and Edinburgh (hip fracture patients). Of the 273 proteins identified, 16 were dysregulated in eight or more delirium subjects across both cohorts. Several proteins involved in the inflammatory response were also upregulated in the majority of those with delirium.
Another proteomics study (Westhoff et al., 2015) included two different Dutch cohorts with acute hip fracture (preoperative delirium was excluded), for derivation and validation of changes found with proteomics. Of the 17 proteins identified as different in the proteomics analysis between those with and without delirium, none were confirmed as different with immunoassay in the validation cohort.
End products of delirium
Markers of neuronal cell death
Older medical patients with prolonged delirium and a control group of outpatients with AD but no delirium were studied in Caplan et al. (2010) . CSF lactate, protein, glucose, S100 calcium-binding protein B (S100B, a marker of CNS injury and astrogliosis) and neuron-specific enolase (NSE) were measured. They found higher CSF lactate in the delirium group, lower NSE, higher protein and no difference in S100B and glucose. Of note, the group with delirium was acutely unwell compared with the outpatient dementia group; therefore, differences may be due to the general effects of acute illness rather than delirium. S100B has also been measured in hip fracture patients in two different studies. Hall et al. (2013) found that S100B concentrations were higher in those with preoperative delirium, although there was no difference between those with and without delirium at any stage during the perioperative period. Another found no significant difference in S100B between patients with or without (predominantly postoperative) delirium (Beishuizen et al., 2015) .
Discussion
The 22 studies identified in this review reveal a small but growing literature, in which many of the important hypotheses in delirium pathogenesis have been examined, but from which few firm conclusions can currently be drawn. The observational nature of all studies means causality cannot be established. The populations studied are heterogeneous, and studies varied in their risk of bias. We will now briefly discuss what this literature suggests regarding delirium pathophysiology.
Risk markers
Dementia is one of the strongest risk factors for delirium (Ahmed et al., 2014; Fong et al., 2015) . However, of the three studies that examined whether levels of established CSF markers for dementia were associated with risk of delirium only Idland et al. showed a convincing relationship (Idland et al., 2017) . These findings may be related to the presence of incipient dementia, and future studies should take this into account.
Disease markers of delirium
Several of the studies support the hypothesis of neurotransmitter imbalance in delirium. The monoamines (dopamine, serotonin and noradrenaline) have important roles in attention and cognition, cognitive domains affected in delirium (Maldonado, 2013) . The results in Koponen et al. (1994c) support an excess of serotonin in delirium. The findings of increased levels of precursor amino acids in Watne et al. (2016) suggest a downstream role for serotonin and for a generally higher monoaminergic tone in delirium. The association of high dopamine metabolites with psychotic features in Ramirez-Bermudez et al. (2008) supports a role in these symptoms of delirium, if not the whole syndrome. These findings have potential therapeutic implications, and replication studies would be valuable.
Loss of somatostatin signalling appears to have a role in dementia, and transient loss may be implicated in delirium (Koponen et al., 1994b) . There may be a fall in beta-endorphin signalling in delirium, but it is difficult to conclude that these changes are related to delirium rather than dementia (Koponen and Riekkinen, 1990) .
The findings in Pearson et al. (2010) support the hypothesis that delirium is associated with elevated CNS cortisol levels.
The neuroinflammatory hypothesis of delirium is a leading hypothesis, whereby a brain made vulnerable by neurodegenerative disease or ageing responds to peripheral inflammatory stimuli with a greater central inflammatory response, manifesting in exaggerated sickness behaviour and delirium (Cunningham and Maclullich, 2013) . In order to test this hypothesis in human studies, animal modelling (Cunningham et al., 2005; Godbout and Johnson, 2006) and hypothesis papers (Cerejeira et al., 2010) would predict that CSF IL-1, IL-6 and tumor necrosis factor-α should be elevated and IL-10 should be reduced in delirium. Elevated IL-1β was found in Cape et al. (2014) , with a higher ratio in CSF : serum, but it was not detected in MacLullich et al. (2011) nor Westhoff et al. (2013) . Because IL-1β is often hard to detect, its endogenous antagonist IL-1ra could be seen as a marker of recent IL-1β activity, as it is usually released after IL-1β to limit the inflammatory response (Allan et al., 2005) . Westhoff et al. (2013) found lower CSF IL-1ra levels in those about to develop delirium, whereas Cape et al. (2014) found higher CSF IL-1ra levels in those with active delirium, possibly indicating that a lower baseline level increases the risk of developing delirium whereas during active delirium, the higher levels may indicate either an endogenous response to an initial spike of IL-1β or a neuroprotective response to the insult of delirium or the inflammatory and traumatic response. IL-6 was reduced in Westhoff et al. (2013) , not significantly different in Neerland et al. (2016) , and elevated in the sole patient with delirium in the Hirsch longitudinal study (Hirsch et al., 2016) . Tumor necrosis factor-α and IL-10 were both not detected in MacLullich et al. (2011) and not significantly different (in small numbers) in Westhoff et al. (2013) . More indirectly, the findings of the Poljak proteomics analysis that several of the proteins involved in the inflammatory response are upregulated in delirium also supports this notion (Poljak et al., 2014) , and the finding by Hall et al. (2016) that neopterin is highest in delirium superimposed on dementia lend some support to the idea that peripheral inflammatory insults may lead to an exaggerated central inflammatory response. However, the Westhoff proteomics study highlights the difficulties in this research area, with none of the candidate findings validated (Westhoff et al., 2015) .
Examining the evidence so far, one does not find a great deal to support the neuroinflammatory hypothesis of delirium; however, it has not been refuted, and many of the studies examining the key biomarkers have been small, with low detection levels. Delirium aetiology, timing of CSF sampling and underlying dementia neuropathology are potential reasons for the conflicting findings in the published literature.
End products of delirium
The finding of raised CSF lactate suggests that a disruption of the brain's normal aerobic metabolism, perhaps resulting from ischaemia or hypoglycaemia, may be involved in delirium (Caplan et al., 2010) . S100B was found to be elevated in those with active delirium after hip fracture (Hall et al., 2013) , but not in medical patients with active delirium compared with patients with dementia who were not acutely unwell (Caplan et al., 2010) , nor in a third study in hip fracture patients with predominantly post-operative delirium (Beishuizen et al., 2015) . In the latter study, the highest levels were in those with active delirium, highlighting that timing of sampling may be crucial. It is therefore unclear whether delirium is associated with astrigliosis or CNS damage. NSE was also lower in patients with delirium, contradicting such a hypothesis.
Delirium severity, subtype and timing of sampling Increasing delirium severity was associated with lower Aβ40/tau and Aβ42/tau ratios (Xie et al., 2014 ), higher HVA (Ramirez-Bermudez et al., 2008 , lactate and NSE levels (Caplan et al., 2010) . In those without prior cognitive impairment, higher AA (Watne et al., 2014) and higher neopterin levels were also associated with more severe delirium. There were no clear relationships between any of the biomarkers and delirium subtype. Timing of CSF sampling according to different phases of delirium was associated with different biomarker findings. CSF collection before delirium was associated with reduced IL-6, IL-1ra, Flt-3 L (Westhoff et al., 2013) , increased IL-1β (Cape et al., 2014) , neopterin and 5-HIAA and amino acid levels , and a low Aβ/tau ratio (Xie et al., 2014) conferred an increased risk of delirium. Collection during delirium was associated with reduced BLI (Koponen and Riekkinen, 1990) and SLI (Koponen et al., 1994b) , increased IL-1ra (Cape et al., 2014) , neopterin , lactate, protein (Caplan et al., 2010) , α1-glycoprotein (Poljak et al., 2014) and S100B (Beishuizen et al., 2015) , lower NSE (Caplan et al., 2010) and in those without prior cognitive impairment, higher CRP (Neerland et al., 2016) .
Methodological issues
Several of the studies could have been influenced by bias or confounding. Sample sizes were generally small. More recent collaborative studies collecting CSF at the onset of spinal anaesthetic have been larger, with lower risk of bias, but several included the same participants as in previous published articles. A diverse range of populations was studied, and generally, patients with delirium were frailer, older and more often had dementia. There is likely to be a high proportion of unrecognised dementia in the cohorts of patients with hip fracture and older medical inpatients. A further potential confounding factor in these heterogeneous groups of patients is the underlying precipitants of delirium.
Serum values were reported in 11 studies. Interestingly, the direction of change in markers measured in both CSF and serum was sometimes at odds, illustrating the limitations in using analyses in blood to measure biochemical changes in the brain. The timing of sampling may be crucial; there may be different pathophysiological processes occurring in a patient who is not yet delirious, compared with new active delirium or prolonged delirium. Some authors have attempted to separate these groups, whereas in some studies, all these phases are included as cases. Given that levels of biomarkers may be fleeting and may change during different phases of the delirium syndrome, longitudinal sampling of CSF might shed more light on the complex relationship between biomarkers and delirium.
In addition to timing, other pre-analytical variables may affect the results, with differences in the handling of CSF samples possibly contributing to the heterogeneity of results. Several potential variables of interest highlighted by work in the AD biomarker field are outlined in Table 4 . Analysis methods are outlined in Table 1 . Whilst proteomic technologies and automated assays are increasingly frequently employed, enzymelinked immunosorbent assay-based technologies remain the cornerstone of many delirium studies and analytical factors are also therefore still very relevant. All authors specified the kits used as a minimum. Several authors specified that analyses were undertaken by a single researcher at the same time point (thus decreasing laboratory practice variability). Analysis of samples in duplicate or triplicate is inconsistently reported, as are coefficients of variation. Analytical variation is often high at low concentrations close to the analytical sensitivity of the assay, and results may therefore be uncertain for some low abundant cytokines.
This review was limited to studies published in English or Norwegian. Despite our extensive search, we might have missed eligible articles. As the authors of this review have been involved in several of the recent published articles, it might make us less objective on the faults of those articles. A strength is that we have insisted on formal delirium diagnosis by DSM or ICD criteria, or a validated method based upon this.
Challenges and implications for future research
Cerebrospinal fluid research in delirium faces several significant challenges. Care must be taken with potential participants who may lack capacity to consent to participation in such studies (Holt et al., 2008) and in particular when an invasive investigation such as CSF examination is proposed. Since 2010, many studies have taken the approach of collecting CSF opportunistically from patients undergoing spinal anaesthetic for surgery. Hip fracture patients are the most studied group. With delirium and dementia being prevalent in this population, we believe this will continue to be an important model for CSF delirium research in the future. An important limitation with all studies recruiting acutely admitted patients is however the lack of opportunity to do objective cognitive testing before admission. Where there is potential concomitant dementia, it is very difficult to determine whether observed changes are related to acute delirium or confounded by underlying dementia pathology (Inouye and Ferrucci, 2006) . Studies including elective patients can readily involve pre-operative cognitive testing, but the prevalence of delirium is much lower. Also, no patients will have ongoing delirium in studies of elective patients, so CSF analyses are limited to giving information regarding risk factors for delirium.
It is important to avoid being too restrictive in performing LP for research purposes in delirium. LP is safe with post-LP headache being the only significant side-effect (less common in older patients; Duits et al., 2016) . Additionally, LP is sometimes carried out in the investigation of delirium, when certain primary brain disorders are suspected. Therefore, with sufficient care and selection of patients, we believe that studies of the CSF in delirium need not be restricted to opportunistic use of clinical samples or only where spinal anaesthesia is being performed.
Future studies need to be informed by prior research, clearly report baseline characteristics of all subjects and ensure blinding wherever possible. In order to carry out subgroup analyses, which are clearly necessary, larger patient cohorts are needed with standardised and detailed methods of recording of predisposing and precipitating factors. Standardised, detailed assessment of delirium presence as well as its severity is essential, including (where possible) ascertainment of the presence or absence of psychotic features, the motoric subtypes and the presumed aetiologies where drug toxicity is a likely major factor. This will allow additional exploration of pathophysiological subtypes. Standardisation of the collection and handling of CSF will facilitate exchange of samples between centres. Ideally, more generalisable populations of medical and surgical patients should be studied. Information about prior cognitive status is important and should always be collected in studies recruiting acutely admitted patients, through documentation of known prior dementia, and use of an informant questionnaire. Details regarding our recommendations for future studies are given in Table 4 .
Conclusion
In recent years, there has been a blossoming of studies examining CSF in delirium. The heterogeneity of the studies precludes firm conclusions regarding the pathophysiology of delirium. Nevertheless, the overall interpretation of the literature supports the vulnerable brain concept, that is, that biomarker evidence of, for example, AD pathology and/or neuroinflammation is associated with delirium. A concerted effort is now required to standardise several aspects of the methodology and reporting of these studies, in order to advance this highly promising avenue of delirium research.
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Key points
• Delirium is a major public health concern, and research on pathophysiological mechanisms is urgently needed.
• Some biochemical changes in the brain are reflected in the cerebrospinal fluid (CSF), and in recent years, there has been a blossoming of studies examining CSF as a method of studying the pathophysiology of delirium.
• The 22 studies identified in this review reveal a small but growing literature, in which many of the important hypotheses in delirium pathogenesis have been examined, but from which few firm conclusions can currently be drawn. Nevertheless, the overall interpretation of the literature supports the vulnerable brain concept. Freezer space needs to be planned in advance. Collection volumes and collection container type and volume, storage aliquot volumes and container type and size should be decided in advance. Aliquot volumes and sample organisation should be considered in advance aiming to minimise freeze-thaw cycles. Sample transfer to the laboratory for processing should be as swift as possible and ideally within 2 h. A potential centrifugation protocol of 2000 g, for 10 min, at room temperature could be considered. Samples should be stored at À80°C. Polypropylene tubes are recommended, and efforts should be made to use the same brand of containers throughout. Transfer methods, for example, dry ice and courier services, may also need to be considered.
Blood samples
Ideally matched serum/plasma and DNA samples should be collected alongside CSF samples. Reporting Methods used should be consistent and explicitly reported. Specifically, time of day, fasting status, needle used, volume and material of collection vessels used, including manufacturer, method of sampling, that is, aspiration versus drop collection, volume of CSF collected, time and temperature to centrifugation, centrifugation details, storage vessel used, aliquot volume, storage temperature and number of freeze-thaw cycles should be reported. Ideally coefficients of variation should be reported.
Collection of clinical data
Reliable and valid delirium assessment against standard criteria using a validated tool is essential, with a preference for collecting additional detail: cognitive testing with reporting of scores and/or untestability; level of arousal measurement; assessment of psychotic features and motoric status; documentation of presumed aetiologies including potential drug toxicity; and assessment of delirium severity. Information regarding dementia status is particularly important. In elective studies, patients should undergo objective cognitive testing before sampling of CSF. In studies recruiting acutely admitted patients, questionnaires such as the informant questionnaire on cognitive decline in the elderly can be used to assess dementia status.
• A concerted effort is now required to standardise several aspects of the methodology and reporting of these studies, in order to advance this highly promising direction in delirium research.
